-
We are back to the same 3 companies again, Johnson and Johnson, Boston Scientific and Abbott, same questions over “patents” and more legal expenses to pass along to consumers in the price of a stent. If these 3 could settle their differences and make some donations for charity instead of all these...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
03-06-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Medical Devices, Pharma, Biotech, FDA, Stents, Recalls, Legal Suits, Investments, Boston Scientific, Microsoft Tags, Johnson and Johson
-
The pilot will start out with a small trial and will graduate to a larger trial based on chronic disease control medications, diabetes, cholesterol, and high blood pressure. Some of the comments in the article stated the messages were annoying but some didn’t mind. The results will be interesting...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
03-02-2010
Filed under:
Filed under: Technology, Insurance, Pharma/FDA News, EMR, drugs, healthcare, Pharma, PHR, Prescriptions, Fines, personal health record, Express Scripts, overcharges, Vitality
-
As mentioned before, Merck is heavy in cash resources and now is buying US firm Millipore. One other item of interest too is that we always think of Merck as a pharma company only, when in fact their chemical division has interests outside of the drug business, as stated in this article Merck is...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-28-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, medicare, Pharma, Merck, Heatlhcare, Medco, Life Sciences, chemicals, Bravo health, Millipore, acquisitions and mergers
-
I am not picking per se here, but gee every time I turn around I keep hearing about one suit after another with appeals, awards, etc. all going back to “patent wars”, and with present economic conditions, who cares. All I know is that consumers end up paying in the long run for all of this and...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-21-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Medical Devices, Pharma, Biotech, FDA, Recalls, Legal Suits, Investments, Boston Scientific, CE Mark, Microsoft Tags, Johnson and Johson
-
Basilea Pharmaceutica and Johnson and Johnson worked together on the drug for MRSA infections and after not meeting quality and monitoring standards with both the FDA and European Regulators, J and J says goodbye to Basilea and you are on your own, no more money. J and J conducted the trials...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-21-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Medical Devices, Pharma, Biotech, FDA, MRSA, Recalls, Legal Suits, Investments, CE Mark, Microsoft Tags, Johnson and Johson, Basilea Pharmaceutica
-
Do you need a test to see if you are suffering from depression? Eli Lilly of course is thinking you should, as is probably every other pharmaceutical company who has an anti-depressant drug on the market. If you are depressed, or I should say diagnosed, well guess what happens. You...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-20-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, Internet, Advertising, antidepressants, Doctors, TV, Algorithms, Eli Lilly, Grassley, Cymbalta, WebMD
-
This purchase puts Walgreens in the New York market. The mergers and acquisitions in healthcare continue to roll. You can see the investor take in this article when you read this last paragraph as to how tight they are tied into their business intelligence algorithmic formulas and their numbers...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-17-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Investors, Pharma, Prescriptions, Wall Street, Mergers and Acquisitions, Walgreens, drug stores, Duane Reade
-
Here’s some more healthcare money being spent on legal suits over ED drugs. You know if pharma keeps up with all these extensive legal battles it might begin to start depleting some profits and of course it keeps the cost up there for us. There’s an appeal process too and this goes back to...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-16-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Medical Devices, Pharma, Viagra, R and D, Patents, ED, erectile dysfunction, healthare, Goats, Horny Goat Weed, Cialis, Coffee, court cases, herb, trademark
-
If you are not aware this is the treatment used for Herpes and all of this began back in 2005, so how long these legal issues go on and all the money spent, which ends up coming down the line to use as consumers in what we pay for drugs. I think these long legal court battles that keep the price...
-
The Jupiter study was one that literally shook up healthcare and one of the potential side effects is diabetes and muscles that hurt with the use of statins, but it appears the FDA says it’s ok for our muscles to hurt as you are going to lower your odds of heart disease, so us as patients need to have...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-13-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Physician, healthcare, Heart Attack, Pharma, Heart Disease, Prescriptions, Patient, stroke, tomatoes, Crestor, Jupiter report, LDL, cardiovascular disease, cholesteroal, COQ10
-
If you were not aware of this fact you would think it was the opposite, but it’s true, pharmacies make more money from generic drugs. This year with many drugs coming off patent, this should give additional revenues to drug stores and pharmacies. So on the brand name drugs, who keeps most...
-
We kind of have a similar situation here in the US, but ours is done through Pharmacy Benefit Managers and the hitch here too is compliance with tracking who is refilling their prescriptions, so whoever is inquiring knows that at least the prescriptions are being filled, now whether or not they are actually...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
02-08-2010
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Pharma, Pfizer, Pricing, Profits, healthcare reform, compliance, Pharmacy Benefit manager, Novartis, eCard, drug discounts. generic drugs, ePill
-
Wait a minute, don’t these same companies have business models to sell painkillers? As you can see pharma suggested more education, which is always a good thing and there has been talk along with one company submitting a reformulated version of a drug to the FDA for approval. Pharma no doubtedly...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
01-31-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Pills, FDA, medication, Heatlhcare, Risk Management, Business Models, prescription drugs, pain killers
-
I don’t watch that much television but when I do it’s usually catching late night television like Nightline or one of the talk shows and you know what, all I see are these ridiculous ads about “Depression”. The one that really gets me is the one with the video with the person blending into the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
01-28-2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Pharma, Marketing, Heatlhcare, Politics, television, economic depression, anti depressants, FDA pharma
-
A disappointment for Merck and this is not the only patent tied up in the legal system today, Singulair is another one where the patent is being questioned. Merck plans to appeal the case according to the article, ho hum, more legal cases to drive up the cost of the medicine we need. BD ...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
01-26-2010
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Pharma, FDA, Generic Drugs, Merck, Patents, Amgen, Intellectual property, Teva, legal cases